Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30155195 | 1.00 | KDM4C (0.62) | KDM4CALDH1A1MAPTL3MBTL1RAB9A | |
| Hydrochloric Acid SCHEMBL700397 | 0.98 | KDM4C (0.60) | KDM4CALDH1A1MAPTL3MBTL1RAB9A | |
| SCHEMBL14480939 | 0.88 | KDM4C (0.57) | KDM4CALDH1A1MAPTL3MBTL1RAB9A | |
| Tetrahydrofuran SCHEMBL28241044 | 0.88 | KDM4C (0.51) | KDM4CALDH1A1MAPTL3MBTL1RAB9A | |
| SCHEMBL28426040 | 0.84 | ALDH1A1 (0.51) | KDM4CALDH1A1MAPTL3MBTL1RAB9A | |
| SCHEMBL18135104 | 0.83 | GAA (0.56) | KDM4CRAB9AGRM5GAAMEN1 | |
| SCHEMBL6386120 | 0.82 | KDM4C (0.52) | KDM4CALDH1A1MAPTL3MBTL1RAB9A | |
| SCHEMBL1054692 | 0.81 | KDM4C (0.58) | KDM4CALDH1A1MAPTL3MBTL1RAB9A | |
| SCHEMBL163711 | 0.81 | KDR (0.48) | KDM4CALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL25992871 | 0.81 | KDR (0.51) | KDM4CRAB9ANPC1GRM5GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 907 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120082897-A | Preparation method for electrochemically synthesizing N-substituted pyridine-2-formamide | 九洲药业(杭州)有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-119241427-A | Method for comprehensively and efficiently synthesizing anticancer drug regorafenib | 董帅圻 | 2025-01-03 | — | — | CN | claimed |
| CN-118108667-A | Preparation method of regorafenib | 南京法恩化学有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-114957111-B | Preparation method of N-methyl-4-chloropyridine-2-formamide | 扬州市普林斯医药科技有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-117447395-A | Method for preparing sorafenib key intermediate by utilizing micro-channel continuous flow | 山东安弘制药有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-117285460-A | Method for preparing regorafenib intermediate by using continuous flow reaction technology | 重庆药友制药有限责任公司 | 2023-12-26 | — | — | CN | claimed |
| CN-114957111-A | Preparation method of N-methyl-4-chloropyridine-2-formamide | 扬州市普林斯医药科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114539141-A | Preparation method of sorafenib | 南京焕然生物科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| US-10822305-B2 | Process for the preparation of 4-(4-amino-3-fluorophenoxy)-N-methylpyyridine-2-carboxamide | BAYER HEALTHCARE LLC (US) | 2020-11-03 | — | — | US | claimed |
| CN-108997209-B | Preparation method of regorafenib | 山东罗欣药业集团恒欣药业有限公司 | 2020-08-04 | — | — | CN | claimed |
| WO-2015049698-A2 | PROCESS FOR REGORAFENIB | HETERO RESEARCH FOUNDATION (IN) | 2015-04-09 | — | — | WO | claimed |
| US-20130210865-A1 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-15 | — | — | US | claimed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | claimed |
| EP-2528899-A2 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE | Ranbaxy Laboratories Limited (IN) | 2012-12-05 | — | — | EP | claimed |
| CN-102311384-A | Preparation method of sorafenib | XIANGZHEN BIOTECHNOLOGY CO LTD | 2012-01-11 | — | — | CN | claimed |
| WO-2011092663-A2 | 4-(4-{3-[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]UREIDO}PHENOXY)-N2-METHYLPYRIDINE-2-CARBOXAMIDE DIMETHYL SULPHOXIDE SOLVATE | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | claimed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | claimed |
| EP-2195286-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | Cipla Limited (IN) | 2010-06-16 | — | — | EP | claimed |
| WO-2009034308-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2009-03-19 | — | — | WO | claimed |
| CN-101302193-A | Entironment-friendly preparation of sorafenib intermediate | SHANGHAI HWASUN LIFE SCIENCE C (CN) | 2008-11-12 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210865-A1 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE | SRMS, SRM, BRAF | KDM4C 114/4885ALDH1A1 796/4885MAPT 2270/4885 |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | BRAF, RAF1, ARAF | KDM4C 2789/4885ALDH1A1 2911/4885MAPT 3477/4885 |
| US-10822305-B2 | Process for the preparation of 4-(4-amino-3-fluorophenoxy)-N-methylpyyridine-2-carboxamide | DNPEP, NPEPPS, TET3 | KDM4C 10/4885ALDH1A1 1840/4885MAPT 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.